KOSDAQRetail & Consumer035080

Gradiant

₩11,130▲ 5.10%2026-11-18 close
Market Cap
₩124.4B
Turnover
₩300M
Volume
20K
Shares out.
11.2M
PER
—
PBR
0.3×
EPS
-₩1,016
Dividend Yield
1.90%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩200 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue up four straight quarters, profit recovery still early

Gradiant swung to an operating profit of KRW 11.4 billion in Q3 2026, but attributable net losses have run for three straight years and total KRW 11.6 billion over the last four quarters, so the durability of the recovery still needs to be confirmed.

  1. 1

    Q3 2026 revenue reached KRW 1.08 trillion, up 40.7% year on year, and operating profit of KRW 11.4 billion compares with an operating loss of KRW 6.24 billion in Q3 2025.

  2. 2

    Annual revenue fell from KRW 3.58 trillion in 2022 to KRW 3.06 trillion in 2025, a decline for three straight years, with 2025 the smallest year of the period.

  3. 3

    Operating losses were recorded in both 2024 (KRW 5.51 billion) and 2025 (KRW 29.6 billion), and attributable net losses have run for three straight years since 2023.

  4. 4

    The debt ratio (total liabilities to total equity) rose to 141.5% at the end of 2025 from 122.2% in 2024, while operating cash flow turned from -KRW 30.4 billion in 2024 to KRW 12.9 billion in 2025.

  5. 5

    The business is organized around subsidiaries spanning e-commerce (iMarketKorea), health functional foods, organoid-based bio research and an advanced industrial complex project.

02

Business structure

Gradiant, founded in 1997 and listed on KOSDAQ in 1999, is a mid-sized company whose main businesses are subsidiary management and the development, manufacturing and sale of health functional foods.

It acquired a stake in Envipostech in 2025, bringing that company into its consolidated group, and it now holds 29 consolidated subsidiaries. In e-commerce, its subsidiary iMarketKorea is expanding strategic purchasing consulting and industrial goods distribution services on the back of a purchasing agency system.

In bio, its organoid subsidiary, established in April 2022 as a pharmaceutical research and development company, is preparing to commercialize contract non-clinical testing based on patient-derived organoids.

The company said it hired a former global clinical development specialist as chief strategy officer to upgrade its drug evaluation services for customers' drug development. Consolidated R&D spending rose from KRW 11.45 billion in 2024 to KRW 11.79 billion in 2025.

In industrial real estate, it is developing the first phase of an advanced industrial complex of about 70,000 pyeong, and it previously said construction would start in the second half of 2025.

The portfolio spans e-commerce, health foods, bio and industrial complexes, so no single competitor set describes the whole company, and the competitive picture differs by segment.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩765B-₩6.2B−0.8%
2025Q4₩811.2B-₩13.8B−1.7%
2026Q1₩843.3B₩5.8B0.7%
2026Q2₩1T₩7.8B0.8%
2026Q3₩1.1T₩11.4B1.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩3.6T₩14.6B₩326.7B0.4%55.4%100.6%
2023₩3.4T₩2.9B-₩15.8B0.1%−2.9%127.5%
2024₩3.3T-₩5.5B-₩40.4B−0.2%−8.1%122.2%
2025₩3.1T-₩29.6B-₩35.8B−1.0%−8.1%141.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a reported basis, annual revenue fell from KRW 3.58 trillion in 2022 to KRW 3.42 trillion in 2023 (down 4.5%), KRW 3.32 trillion in 2024 (down 3.1%) and KRW 3.06 trillion in 2025 (down 7.7%), a decline for three straight years. 2022 was the largest year and 2025 the smallest.

Operating profit fell from KRW 14.6 billion in 2022 to KRW 2.91 billion in 2023 (down 80.0%), then turned to an operating loss of KRW 5.51 billion in 2024. The loss widened to KRW 29.6 billion in 2025. The operating margin declined from 0.4% in 2022 to 0.1% in 2023, -0.2% in 2024 and -1.0% in 2025.

The company cited a temporary operating deterioration at a consolidated subsidiary as the main reason for the 2025 earnings swing.

Attributable net income of KRW 326.7 billion in 2022 became an attributable net loss of KRW 15.8 billion in 2023, followed by losses of KRW 40.4 billion in 2024 and KRW 35.8 billion in 2025.

Because 2022 attributable net income far exceeded operating profit of KRW 14.6 billion, non-operating items appear to have weighed heavily that year.

Net income including non-controlling interests was KRW 338.9 billion in 2022 and a net loss of KRW 24.7 billion in 2025, a different trajectory from the attributable measure.

By quarter, the operating loss was KRW 6.24 billion in Q3 2025 and KRW 13.8 billion in Q4 2025 before turning to an operating profit of KRW 5.81 billion in Q1 2026.

Operating profit then rose to KRW 7.84 billion in Q2 2026 (up 34.8% from the prior quarter) and KRW 11.4 billion in Q3 2026 (up 45.6%), two straight quarters of growth.

Attributable net income was KRW 4.39 billion in Q2 2026 and KRW 2.29 billion in Q3 2026, down 47.9% from the prior quarter, and attributable net losses over the last four quarters total KRW 11.6 billion. Operating cash flow moved from -KRW 30.4 billion in 2024 to KRW 12.9 billion in 2025.

05

Industry analysis

Gradiant's businesses span industrial e-commerce and distribution, health functional foods, bio research and industrial complex development, and each follows a different end market.

Although it sits in the consumer and distribution sector, its structure is closer to a multi-subsidiary group than to a mass-market consumer goods company. iMarketKorea, its e-commerce subsidiary, is absorbing industrial goods distribution demand through a purchasing agency system, and the company describes this as a pillar of steady revenue growth.

Whether 2026 revenue gains came from higher transaction volumes or from price effects cannot be separated from the reported annual and quarterly figures, so segment disclosures need to be checked. In the first half of 2025, revenue had fallen 13.5% year on year and the operating loss had widened sharply.

The bio segment has set improving the predictive power of its models and expanding partnerships with global pharmaceutical and CRO companies as its agenda, so its position in non-clinical CRO work is still at an early stage.

Health functional foods are affected by consumer spending and changes in distribution channels, and their share of total revenue is a point to check in segment disclosures.

Compared with large distribution and trading companies in the same consumer and distribution sector, the subsidiary mix that extends into bio and industrial complexes is a distinguishing feature.

The current position in the industry cycle is difficult to define, so quarterly revenue trends and segment profit contributions should be read together.

06

Outlook

Of the company's stated plans, three can be verified. First, the first phase of the advanced industrial complex, about 70,000 pyeong, was slated to start construction in the second half of 2025, with the aim of offering industrial materials and logistics total solutions to tenant companies.

Its progress and the timing of any revenue contribution are points to check in future periodic reports. Second, the bio subsidiary is preparing to commercialize contract non-clinical testing based on patient-derived organoids, and hiring a chief strategy officer has added clinical development capacity.

Third, iMarketKorea is widening its strategic purchasing consulting and industrial goods distribution services. On earnings, the key question is whether the Q3 2026 operating profit continues beyond Q4.

Full-year 2026 results, including Q4, will be disclosed in the 2026 annual report, which based on prior filing dates is expected around March 2027. Operating profit is improving, but attributable net income fell in Q3 from Q2, so how the gap between the two is narrowed is central.

Whether the operating margin improves along with revenue is the next point to check. R&D spending rose to KRW 11.79 billion in 2025, so cost pressure may persist as bio expansion continues. Financial results from these projects may take time to appear, so each stage should be followed in the disclosures in sequence.

07

Valuation

PER
—
PBR
0.3×
ROE
-2.6%
EPS
-₩1,016
BPS
₩38,944
Dividend per share
₩200

Valuation becomes clearer when split into earnings-based and asset-based views. Because attributable net losses over the last four quarters total KRW 11.6 billion, the price-to-earnings ratio cannot be calculated. Attributable net income was positive in Q2 and Q3 2026, but the four-quarter total remains a loss.

The price-to-book ratio sits well below the level of book value per share, meaning the share price is low relative to book capital. The debt ratio rose from 122.2% in 2024 to 141.5% in 2025, so the debt burden should be weighed alongside any asset-based comparison.

Total equity at the end of 2025 was KRW 723.2 billion, of which the equity attributable to controlling shareholders was KRW 442.5 billion. A 2025 industry comparison showed the dividend yield above the KOSDAQ distribution sector average.

Earnings-based comparisons remain limited until attributable net income builds up consecutive profitable periods, so asset-based comparisons are used more often.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Operating profit turnaround

Operating profit turned positive at KRW 5.81 billion in Q1 2026, then rose to KRW 7.84 billion in Q2 and KRW 11.4 billion in Q3, two straight quarters of growth. Revenue also rose for four consecutive quarters to KRW 1.08 trillion in Q3 2026.

Compared with the operating loss of KRW 6.24 billion in Q3 2025, the direction of operating results has changed.

Cash flow back in positive territory

Operating cash flow moved from -KRW 30.4 billion in 2024 to KRW 12.9 billion in 2025. Cash generation recovered even while operating losses continued. The improvement covers only one year, so its persistence should be checked in future periodic reports.

Bio commercialization and partnerships

The organoid subsidiary is preparing to commercialize contract non-clinical testing based on patient-derived organoids. Hiring a chief strategy officer added clinical development experience, and a global collaboration on an Alzheimer's disease organoid model has been reported. If the drug evaluation services are commercialized, they could add a new diversification driver.

09

Bear factors

Three years of attributable net losses

Attributable net losses were KRW 15.8 billion in 2023, KRW 40.4 billion in 2024 and KRW 35.8 billion in 2025, three straight years of losses. The operating loss widened to KRW 29.6 billion in 2025. Attributable net losses over the last four quarters total KRW 11.6 billion, so the accumulated loss remains.

Revenue recovery still early

Annual revenue fell from KRW 3.58 trillion in 2022 to KRW 3.06 trillion in 2025. Quarterly revenue has risen for four straight quarters but has not returned to the 2022 level. The 40.7% increase in Q3 2026 is measured against the KRW 765 billion base of Q3 2025, which should be kept in mind.

Rising debt burden

The debt ratio rose from 100.6% in 2022 to 141.5% in 2025, and total liabilities at the end of 2025 were KRW 1.02 trillion. Against total equity of KRW 723.2 billion, equity attributable to controlling shareholders was KRW 442.5 billion. Whether capital capacity narrows while losses persist is a key point to watch.

10

Risk factors

Earnings durability

The Q3 2026 operating profit reflects two straight quarters of growth, but attributable net losses over the last four quarters total KRW 11.6 billion. Attributable net income fell 47.9% in Q3 from Q2.

If the gap between operating profit and attributable net income does not close, the operating turnaround may not translate into a sustained earnings recovery.

Subsidiary earnings volatility

A temporary operating deterioration at a consolidated subsidiary can swing consolidated earnings significantly. With 29 consolidated subsidiaries and an additional affiliate brought in through the 2025 stake acquisition, there are many sources of volatility in consolidated results. Which subsidiary drives profit or loss has to be checked in quarterly breakdowns.

Investment and financial burden

The first phase of the industrial complex and the bio commercialization both require capital and time. R&D spending rose to KRW 11.79 billion in 2025, and the debt ratio reached 141.5%. If investment returns arrive late, the financial burden could grow, so capital spending and the debt trend should be read together.

11

What to watch next

  1. Around March 2027

    The 2026 annual report will confirm full-year 2026 results and Q4 results. The key question is whether the operating profit recorded through Q3 2026 holds in Q4.

  2. Around May 2027

    The Q1 2027 quarterly report will be filed. It will show operating profit against the same quarter a year earlier, and whether attributable net income stays positive.

  3. Around August 2027

    The Q2 2027 quarterly report will be filed. It is the point to check whether the operating margin improves along with revenue and how the debt ratio moves from 141.5%.

12

Overall view

Gradiant's Q3 2026 results showed revenue of KRW 1.08 trillion, up 40.7% year on year, and operating profit of KRW 11.4 billion, a swing from loss to profit. Operating profit rose for two straight quarters after turning positive in Q1 2026, and revenue rose for four consecutive quarters.

On an annual basis, however, revenue fell for three straight years from KRW 3.58 trillion in 2022 to KRW 3.06 trillion in 2025, and operating losses continued for two years. Attributable net losses have occurred for three straight years since 2023 and total KRW 11.6 billion over the last four quarters.

On the financial side, the debt ratio rose to 141.5% at the end of 2025 from 122.2% in 2024, while operating cash flow turned positive at KRW 12.9 billion in 2025. Strengths include the operating profit trend and improved cash flow, while weaknesses include accumulated attributable net losses and a heavier debt burden.

The next points to check are the 2026 annual report, expected around March 2027, and the Q1 2027 quarterly report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.fnguide.com
  2. comp.wisereport.co.kr
  3. vegannews.co.kr
  4. comp.fnguide.com
  5. comp.wisereport.co.kr
  6. thinkpool.com
  7. google.com
  8. markets.hankyung.com
  9. news.nate.com
  10. investing.com
  11. tradingkey.com
  12. tradingkey.com
  13. quiverquant.com
  14. investing.com
  15. tradingkey.com
  16. datatooza.com
  17. tradingkey.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis